Abstract

Activated leukocyte cell adhesion molecule (ALCAM, CD166) is expressed in various tissues, cancers, and cancer-initiating cells. Alterations in expression of ALCAM have been reported in several human tumors, and cell adhesion functions have been proposed to explain its association with cancer. Here we documented high levels of ALCAM expression in human thyroid tumors and cell lines. Through proteomic characterization of ALCAM expression in the human papillary thyroid carcinoma cell line TPC-1, we identified the presence of a full-length membrane-associated isoform in cell lysate and of soluble ALCAM isoforms in conditioned medium. This finding is consistent with proteolytically shed ALCAM ectodomains. Nonspecific agents, such as phorbol myristate acetate (PMA) or ionomycin, provoked increased ectodomain shedding. Epidermal growth factor receptor stimulation also enhanced ALCAM secretion through an ADAM17/TACE-dependent pathway. ADAM17/TACE was expressed in the TPC-1 cell line, and ADAM17/TACE silencing by specific small interfering RNAs reduced ALCAM shedding. In addition, the CGS27023A inhibitor of ADAM17/TACE function reduced ALCAM release in a dose-dependent manner and inhibited cell migration in a wound-healing assay. We also provide evidence for the existence of novel O-glycosylated forms and of a novel 60-kDa soluble form of ALCAM, which is particularly abundant following cell stimulation by PMA. ALCAM expression in papillary and medullary thyroid cancer specimens and in the surrounding non-tumoral component was studied by western blot and immunohistochemistry, with results demonstrating that tumor cells overexpress ALCAM. These findings strongly suggest the possibility that ALCAM may have an important role in thyroid tumor biology.

Introduction

Thyroid tumours are the most frequent malignancies of the endocrine system [1]. The most common type is papillary thyroid carcinoma (PTC), a well-differentiated tumor arising in follicular cells that accounts for 80–90% of all thyroid malignancies. Medullary thyroid cancer (MTC) accounts for 5 to 10 percent of thyroid cancer cases and arises from calcitonin-producing C cells [2].

The epithelial to mesenchymal transition (EMT) is an essential step for invasiveness and progression in these tumors [3;4]. Crucial to this transition is the downregulation of cell–cell contacts, most notably E-cadherin–based adhesion [5]. Indeed, adhesion pathways and their altered regulation by β-catenin and Wnt signaling are important in the progression of thyroid tumors [6].

Among cell adhesion molecules, the neuron–glia-related cell-adhesion molecule (NgCAM) has been shown to be involved in thyroid carcinogenesis [7–9]. The loss of neural cell adhesion molecule CD56/NCAM expression is significant in papillary carcinoma (up to 100%), and such loss can serve as a specific and sensitive marker of PTC [10;11]. This gradual change seems to parallel a decrease in nuclear expression of thyroid transcription factor (TTF-1), an epithelial-specific transcription factor which regulates the changes in gene expression patterns that underlie EMT [12].

This report focuses on the activated leukocyte cell adhesion molecule (ALCAM or CD166), a member of the immunoglobulin superfamily, [13] in papillary and medullary thyroid tumors. Altered expression of ALCAM has been associated with differentiation state and progression in many tumors [14–21]. In addition, ALCAM is a marker of cancer stem cells and its expression at the tumor cell surface has been correlated with shortened survival in colon-rectal cancers [17;22] and with the vertical growth phase of progression in cutaneous melanoma [23].

On the contrary, in breast [24–26] and ovarian cancer [20] ALCAM cytoplasmic overexpression and low membrane expression were associated with disease progression. Therefore ALCAM at the cell surface plays a divergent role in the progression of different tumor types. Very recent data indicate that both transfection of mimics of microRNA-192 or -215 or ALCAM-specific siRNA significantly inhibit ALCAM expression and increase migration in a cell line model of gastric cancer [27]. Collectively these data suggest that the ALCAM relocation...
from the cell membrane to cytoplasm might ultimately enhance
the migratory properties of malignant cells facilitating metastatic
dissemination in several cancers.

In this context, we have previously demonstrated that ALCAM
is released from epithelial ovarian cancer (EOC) cells by a
metalloprotease-dependent mechanism, leading to the generation
of a natural soluble form of ALCAM that contains the greater part
of the ectodomain. We have also shown that ALCAM shedding
from the EOC can be enhanced by stimuli such as pervanadate
(PV), phorbol myristate acetate (PMA), and epidermal growth
factor (EGF) and can be blocked by inhibitors of ADAMs and by
ADAM17/TACE silencing [28]. The clinical relationship of
membrane ALCAM loss with progression in ovarian and breast
cancer may also relate to the process of ALCAM shedding by
ADAM17/TACE. Indeed, ADAM17/TACE inhibitors reduced
ovarian carcinoma cell motility in vitro [28]. In addition, shedding
of ALCAM results in the increase of sALCAM in the serum of
ovarian [28] and breast cancer patients [21], suggesting a potential
role of sALCAM as tumor biomarker, although lower levels are
also present in the plasma of healthy individuals [29]. Besides
enzymatic shedding, a recent report indicates that DNA-
methylation of ALCAM promoter might also be involved in
surface ALCAM down-regulation and breast cancer metastases
development [24].

In view of the role of ALCAM dynamics in some human
tumors, we studied its expression in thyroid tumors, which had not
been previously explored. We also specifically investigated whether
ADAM17/TACE was responsible for shedding of ALCAM in
thyroid cancer cells and we found the existence of a novel 60-kDa
soluble form of ALCAM. Finally, we studied the regulation of
ADAM17/TACE activity by PMA and EGF stimulation, and the
effects of ADAM17/TACE blockade in migration and invasion.

**Results**

**TPC-1 cell line expresses ALCAM isoforms**

Western blot analysis revealed the expression pattern of
ALCAM in total cell lysate and in conditioned medium of the
TPC-1 cell line (Fig. 1A). A single band of 105 kDa, corresponding
to the fully glycosylated isoform in the cell lysate and two distinct
isoforms of 96 and 60 kDa, respectively, were detected in
conditioned medium. These results were consistent with those
obtained with the SKOV-3 cell line known to express high levels
of ALCAM (Fig. 1A). We then hypothesized that the 96-kDa
isoform could correspond to a natural soluble form of ALCAM,
which contains the greater part of the ectodomain, [28] while the
60-kDa isoform could correspond to a new isoform resulting from
an alternative cleavage or differential glycosylation.

The glycosylation patterns of the ALCAM isoforms in cell
lysates and conditioned medium were characterized by treatment
with a mixture of endo-O-glycosidase and sialidase in the absence
(Fig. 1B) or presence of PNGaseF (Fig. 1C), followed by western

![Figure 1. Western blot analysis of ALCAM expression in lysate and conditioned medium of TPC-1 cell line.](image-url)

(A) Analysis of TPC-1 cell lysate (Lys) and conditioned medium (CM) using anti-ALCAM antibody. Arrow indicates membrane-localized ALCAM isoform in lysate, and arrowheads indicate shed-ALCAM isoforms in CM, respectively. The SKOV-3 cell line was used as positive control. (B) TPC-1 cell lysate and CM were treated or not with a mixture of O-glycosidase (O) and sialidase (S) and analyzed by western blot using anti-ALCAM antibody. Continuous arrows indicate membrane and shed ALCAM forms before digestion, and dashed arrows indicate digestion products. (*) indicates less evident bands of ALCAM in CM. (C) TPC-1 cell lysate and CM were treated or not with O-glycosidase (O), sialidase (S), or PNGaseF (F) and analyzed by western blot using anti-ALCAM antibodies. Continuous arrows indicate membrane and shed ALCAM forms before digestion, and dashed arrows indicate digestion products.

doi:10.1371/journal.pone.0017141.g001
Protein shedding can be stimulated by calcium ionophores as ionomycin, [30] or by APMA (4-aminophenylmercuric acetate) [31] or PMA [28]. To investigate the regulation of ALCAM shedding, we treated the TPC-1 cell line with ionomycin and PMA. Treatment with either ionomycin or PMA increased the total level of soluble ALCAM isoforms (Fig. 2). Intriguingly, the treatment with PMA increased the expression of the 60-kDa ALCAM isoform, suggesting that this previously undescribed soluble form is produced by an alternative and inducible shedding of the 105-kDa ALCAM isoform.

Release of ALCAM is inducible by ionomycin and PMA

We have previously demonstrated that EOC cells constitutively release ALCAM, and that cell treatment with EGF enhances this process, while ADAM17/TACE silencing inhibits it [28]. We then tested the effects of ADAM17/TACE inhibition and activation on ALCAM release in TPC-1 cells. TPC-1 cells indeed expressed ALCAM (Fig. 3A) and transfection of a specific siRNA targeting ADAM17/TACE significantly inhibited ADAM17/TACE protein expression (Fig. 3B) and sALCAM release (49% inhibition, Fig. 3C). We further determined whether epidermal growth factor receptor (EGFR) activation influenced sALCAM release via ADAM17/TACE in TPC-1 cells. To this end, cells were treated with PV or EGF in the presence of CGS (IC50 = 159±9 nmol/L on recombinant ADAM17/TACE in vitro, unpublished data) or solvent (DMSO). EGF increased ALCAM secretion by about 2-fold above spontaneous release at 24 h. Cell stimulation with PV also increased ALCAM release by two-fold within 60 min. In a dose-dependent manner, CGS inhibited ALCAM release induced by both stimuli and also by constitutive shedding (Fig. 3D), suggesting a role for ADAM17/TACE in ALCAM shedding in TPC-1 cells.

ADAM17/TACE involvement in TPC-1 cell motility

We also examined TPC-1 cell motility using the scratch assay in presence of the ADAM17/TACE inhibitor CGS. The analysis revealed that the distance covered by migrating cells was significantly decreased when TPC-1 cells were exposed to the CGS compared to cells exposed to the vehicle (DMSO) (Fig. 4). This result indicates a correlation between TPC-1 motile behavior and ADAM17/TACE activity.

Since the recombinant anti-ALCAM antibody I/F8 increased EOC cells motility in a scratch assay by altering ALCAM adhesive functions [28], we examined its activity on the TPC-1 cell line. However, the use of I/F8 antibody failed to inhibit adhesion to the substrate and migration through an 8 µm pore diameter membrane and motility in the scratch assay (data not shown). The possible reason for the efficacy of ADAM17/TACE inhibitors and for the lack of effect of ALCAM antibody blockade may relate to the ability of ADAM17/TACE to cleave, besides ALCAM, several membrane substrates, including other adhesion molecules of the CAM family [32], which may play a redundant role in TPC-1 cell adhesion and motility.

ALCAM expression in normal and neoplastic thyroid tissues

Western blot analysis indicated a high expression of ALCAM in the TT and MZ-CRC1 cell lines (Fig. 5). We further explored its expression in archival tissue samples from 11 PTCs, 5 MTCs, and 5 normal thyroids (CTRLs). As shown in Fig. 6A, the ALCAM staining pattern appeared to be stronger in tumor samples, especially in MTCs, and revealed several discrete bands ranging from 120 to 100 kDa, probably due to a different level of glycosylation. In particular, in normal thyroid tissues, ALCAM staining was weaker and associated with a protein of ~100 kDa. To better clarify the nature of the ALCAM isoforms, we performed a deglycosylation of the lysates of three TPCs, two MTCs, and three normal thyroids with PNGaseF, removing N-linked sugars and leaving the protein backbone. ALCAM immunoblotting of the deglycosylated normal thyroid samples (Fig. 6B) showed a principal band corresponding to the precursor of 68 kDa. In contrast, in deglycosylated tumor samples, we detected multiple bands, probably the result of a partial deglycosylation or degradation of the putative membrane-associated 105-kDa isoform [28] and/or a concomitant presence of other unknown post-transduction modifications. These results confirmed that the multiple isoforms observed in tumor samples exhibited a prevalence associated with differential N-linked glycosylation (Fig. 6A and B).

To assess ALCAM expression and localization in normal and neoplastic thyroid tissues, we performed HIC analysis on formalin-fixed and paraffin-embedded tumoral sections of four PTCs and two MTCs. In comparison with peritumoral thyroid tissue, ALCAM was overexpressed in all PTC and MTC tissues. With regard to cellular localization, in MTC the surrounding non-

Figure 2. Changes in ALCAM expression induced by ionomycin or phorbol myristate acetate (PMA). Total lysates (Lys) and conditioned medium (CM) from TPC-1 cells, treated or not with 1 µM ionomycin (iono) or 50 ng/mL PMA for 2 h, were resolved by 3–8% SDS-PAGE and immunoblotted with ALCAM antibody. Both treatments led to an increase of secreted ALCAM isoforms; especially PMA induced a gain of 60-kDa isoform expression. Arrow indicates the membrane-localized ALCAM isoform in lysate, and arrowheads indicate shed-ALCAM isoforms in CM, respectively. Beta-actin was used as a loading control.

doi:10.1371/journal.pone.0017141.g002
tumor tissue (Fig. 7A) and the corresponding tumor tissue (Fig. 7B) showed membranous positive immunostaining, as in the surrounding non-tumor tissue of PTC (Fig. 7C); while in PTC tumor tissue ALCAM staining was localized at the membrane and in the cytoplasm (Fig. 7D). These results are in agreement with the annotated immunohistochemical patterns in Human Protein Atlas database (www.proteinatlas.org).

We also used IHC to investigate the expression of CD56 and TTF-1 in sequential sections. Intriguingly, we found that in three out of four tested PTCs, both proteins were lost. By contrast, two out of two tested MTCs showed positivity for CD56 and ALCAM and negativity for TTF-1 (Table 1).

Discussion

Over the past decade, alterations in expression of ALCAM have been reported in several human tumors and recently in renal carcinoma and in neuroblastoma primary tumors [33]. We show that ALCAM expression is also modulated in thyroid cancer. Membrane-associated ALCAM isoforms were overexpressed and highly glycosylated in tumors; in contrast, normal thyroid tissue expressed preferentially low glycosylated ALCAM isoforms. ALCAM was also strongly released in conditioned medium. The proteomic characterization of ALCAM isoforms in TPC-1 cells indicated that two soluble isoforms are released into conditioned medium; in addition, it suggested an unpredicted use of O-glycosylation sites, other than the known N-glycosylation, that could be important for both compartmentalization and secretion [34].

IHC confirmed that ALCAM expression was higher in tumors than in adjacent, normal peritumoral thyroid. With regard to cellular localization, ALCAM staining was mostly located in the cell membrane in normal thyroids and in MTCs, while in PTCs was membrane associated and cytoplasmic. This diversity in staining patterns could reflect tumor biology across histologies or grading. On the basis of these data, ALCAM overexpression in neoplastic thyroid tissues, analogously to other tumor types, could be implicated in tumor invasiveness and dedifferentiation processes. This concept is consistent with the loss of CD56 and TTF-1 expression in PTCs, associated with increased tumor invasiveness in vivo [10;35]. Multiple studies have examined ALCAM expression at the transcript and protein levels in tumors. There is an emerging consensus that low membrane level of ALCAM is a bad prognostic marker in breast [24] and ovarian cancer [20]. In this respect, the possibility that the high levels of ALCAM expression in thyroid tumors may indicate a reprogramming in transcriptional activity due the loss TTF-1 may deserve further investigation.

Regarding medullary and papillary thyroid tumors one of the possible mechanisms involved in ALCAM overexpression could be
RET oncogenic activation. However, RET inhibition failed to alter ALCAM levels in TPC-1, suggesting that ALCAM overexpression is not dependent on RET activity and that other factors are likely to be involved (unpublished results).

Instead, we found that EGFR stimulation increases ALCAM secretion in part through an ADAM17/TACE-dependent pathway. We previously demonstrated the expression of EGFR in MTC cell lines and clinical biopsies [36]. In addition, Rodriguez-Antona et al. [37] have reported, based on a large set of MTC cases, that EGFR is significantly overexpressed in metastases compared with primary tumors. EGFR is also expressed in PTCs, and EGFR signaling may represent a molecular target in poorly differentiated thyroid carcinoma cells [38]. Our data indicate that activated EGFR also cooperates in thyroid cancer cell lines with the ADAM17/TACE sheddase in promoting ALCAM shedding and soluble ALCAM release. We previously demonstrated that ADAM17/TACE activity is involved in motility of ovarian carcinoma cells [28].

In the present report we show that inhibition of ADAM17/TACE function through chemical inhibitor also interfered with TPC-1 cell migration.

This is explained by the fact that ADAM17/TACE cleavage of transmembrane proteins such as ALCAM is an essential process controlling many biological functions including cell adhesion and migration. A similar anti-adhesive activity would be also expected by antibody-mediated blockade of ALCAM adhesive functions, which increased ovarian cancer cells motility in a previous report [28]. However, in the case of TPC-1 cells the anti-ALCAM antibody I/F8 failed to augment cell motility. The possible reason of this discrepancy may depend upon the presence of several adhesion molecules, which display redundant functions in cell-cell adhesion and are all substrates of ADAM17/TACE. For example, a previous report showed the expression of ICAM-1 in thyroid carcinoma cells [39].

In parallel studies we observed that TPC-1 cells express a strong mesenchymal phenotype, as evidenced by the expression of mesenchymal cytосkeletal proteins, such as vimentin, and the high deposition of extracellular matrix proteins, including collagens and fibronectin [40]. Consistently with these observations, TPC-1 cells showed elevated levels of β1-integrin and integrin-regulated signaling pathways, which regulate intracellular

---

**Figure 4. CGS decreases TPC-1 cell motility.** Cells were seeded onto cell culture plates, as described in materials and methods. TPC-1 cells were exposed to CGS treatment or vehicle. At cell confluence, a scratch was performed using a 10 μl tip and the wound measured. After a 15 h treatment, the plate area remaining free of cells was measured. The cell-free area accounted for 44.5% of the image when the scratch was applied, P<0.05 versus DMSO control.

doi:10.1371/journal.pone.0017141.g004

---

**Figure 5. ALCAM expression in thyroid cell lines.** Analysis of TT and MZ-CRC1 cell lysates showing ALCAM protein expression in these thyroid cell lines. SKOV-3 and TPC-1 cell lysates were included as controls. Total lysates from each cell line were resolved by 4–12% SDS-PAGE and immunoblotted with anti-ALCAM antibodies. Arrow indicates the fully glycosylated ALCAM isoform. Beta-actin was used as a loading control.

doi:10.1371/journal.pone.0017141.g005
Figure 6. **ALCAM expression in normal and tumor human thyroid tissue samples.** (A) Total protein extracts (30 μg) from 11 papillary thyroid carcinomas (Ca Pap), 5 medullary thyroid carcinomas (Ca Mid), and 5 normal thyroid tissues (Thyroid) were resolved by 4–12% SDS-PAGE, transferred onto a nitrocellulose membrane, and immunoblotted with anti-ALCAM antibody. (*) indicates a non-specific background band. Beta-actin was used as a loading control. (B) Western blot analysis of ALCAM expression of total protein extracts (30 μg) from three PTCs, two MTCs, and three CTRLs, treated (+) or not (−) with N-glycosidase F. Beta-actin was used as a loading control. doi:10.1371/journal.pone.0017141.g006

Figure 7. **Immunohistochemical analysis of ALCAM.** Membranous positive staining in surrounding non-tumor tissue (A and C) and in medullary thyroid carcinomas (MTCs) (B). Cytoplasmic and membranous positive staining in papillary thyroid carcinomas (PTCs) (D). 1, low-power field; 2, high-power field; N (normal tissue), T (tumor tissue). doi:10.1371/journal.pone.0017141.g007
Table 1. Immunohistochemical reactivity of thyroid tumors.

| Case n. | ALCAM | TTF-1 | CD56 | Carcinoma diagnosis |
|---------|-------|-------|------|---------------------|
|         | Cytoplasmic staining | Membranous staining | Nuclear staining | Membranous staining | |
| 1       | -     | +     | -    | +                   | MTC                 |
| 2       | -     | +     | -    | +                   | MTC                 |
| 3       | +     | +     | +    | +                   | PTC                 |
| 4       | +     | +     | -    | -                   | PTC                 |
| 5       | +     | +     | -    | -                   | PTC                 |
| 6       | +     | +     | -    | -                   | PTC                 |

ALCAM, activated leukocyte cell adhesion molecule; PTC, papillary thyroid carcinoma; MTC, medullary thyroid carcinoma.

CD56 and TTF-1 were negative in three out of four PTC cases. MTCs showed comparable positive immunostaining results for CD56 but were completely negative for TTF-1.

Materials and Methods

Ethics Statements

This study, involving human subjects, has obtained ethics approval from Independent Ethics Committee (IEC) of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Reagents, cell culture media, antibodies, and enzymes

Sodium orthovanadate (Na$_3$VO$_4$), PMA, ionomycin, PMSF, and DMSO were supplied from Sigma-Aldrich (Cambridge, MA, USA). I/F8 scFv antibody from Novocastra (Leica; Milan, Italy); anti–TTF-1 antibody was from Sigma-Aldrich (Cambridge, MA, USA). Anti–ALCAM antibody was from BioWhittaker (Lonza; Milan, Italy); and HEPES buffer from sodium pyruvate, L-glutamine, and trypsin-EDTA solution from HyClone (Celbio; Milan, Italy); RPMI 1640, Ham’s F12, DMEM was from Gibco (Invitrogen; Milan, Italy); FBS and FCS (Milan, Italy); and Bradford reagent from BioRad (Milan, Italy). Protease inhibitor cocktail tablets (Complete Mini) from Roche and DMSO were supplied from Sigma-Aldrich (Milan, Italy); and sodium orthovanadate (Na$_3$VO$_4$), PMA, ionomycin, PMSF, and DMSO were supplied from Sigma-Aldrich (Cambridge, MA, USA). I/F8 scFv antibody is described in [42]. Anti–TTF-1 antibody was from Novus Biological (DBA, Milan, Italy). Anti-rabbit IgG, horseradish peroxidase–linked whole antibody (from donkey), anti-mouse IgG, and horseradish peroxidase–linked whole antibody (from sheep) were supplied from GE Healthcare (Milan, Italy); and anti-goat antiserum was from ZYMED Laboratories (Invitrogen; Milan, Italy). N-glycosidase F (PNGaseF) was purchased from New England Biolabs (Celbio; Milan, Italy) and O-glycosidase and α(2→3,6,8,9)neuraminidase (sialidase) from Sigma-Aldrich.

Tissue samples and protein extraction

MTC and PTC specimens and normal thyroid tissues were obtained from 22 patients, who provided written informed consent to participate in the study according to the ethical guidelines of our Institute, after surgery. Tissue samples were pulverized and processed as described in [36].

Preparation of cell lysates

Cells were lysed and processed as described in [36].

Cell cultures

Cell lines were grown as follows: human PTC cell line TPC-1 in DMEM, supplemented with 10% FBS; human MTC cell line TT in Ham’s F12, supplemented with 15% FCS; human MTC cell line MZ-CRC1 in DMEM, supplemented with 10% FCS; human ovarian cancer cell line A2774 [28] and human MTC cell line SKOV-3 (from American Type Culture Collection; Milan, Italy) in RPMI 1640, supplemented with 10% FCS.

Preparation of conditioned media

TPC-1 cells were seeded at 3×10$^4$ cells/cm$^2$ and cultured for 4 d. Medium was removed, and cells were washed four times with PBS and once with serum-free medium. Serum-free DMEM was added and plates incubated for 24 h. The CM was collected, centrifuged at 4000 rpm for 10 min to remove cell debris, and finally concentrated and desalted using a spin column (Agilent Technologies; Milan, Italy).

N-deglycosylation and O-deglycosylation reactions

Cell lysates and CM proteins were O-deglycosylated with a mixture of O-glycosidase and α(2→3,6,8,9)neuraminidase (sialidase), with or without PNGaseF. A total of 100 μg of protein from each sample was treated with 5 mU of O-glycosidase and α(2→3,6,8,9)neuraminidase (sialidase) from Sigma-Aldrich.

Future exploration of ALCAM differential function and regulation in thyroid epithelium cancer and relative metastasis will contribute to a better understanding of whether its dysregulation contributes to disease progression and may provide insight into whether ALCAM has active function in thyroid tumors.

signaling in control of survival, cell-matrix adhesion dynamics and cell migration [40].

Proteolysis of ALCAM in our study generated two sALCAM fragments of different molecular weights, which seemed not derived from differential glycosylation, as treatment with N- and O-glycosidases still yielded two molecular forms. A possible alternative hypothesis is that ALCAM can be cleaved at two distinct sites: one close to the membrane and another in a more membrane-distal region, which yield the 96-kDa and the 60-kDa glycosylated fragments, respectively. Similarly, digestion of immunoprecipitated ALCAM in vitro by recombiant ADAM17/TACE produced a fragment of about 60 kDa, suggesting that the same enzyme may cleave ALCAM in two different sites, in different conditions [33]. PMA stimulation of TPC-1 cells activated ADAM17/TACE activity as detected by the increased release of both 96 and the 60 kDa ALCAM isoforms, supporting a role of protein kinase C (PKC) in regulating ALCAM dynamics [41].

Future exploration of ALCAM differential function and regulation in thyroid epithelium cancer and relative metastasis will contribute to a better understanding of whether its dysregulation contributes to disease progression and may provide insight into whether ALCAM has active function in thyroid tumors.
10 mM of sialidase. An additive treatment with PNGaseF was performed, using 1 U/100 µg of protein.

**SDS-PAGE and western blotting**

The procedures were performed as previously described in [36].

**Drug treatments**

To test effects of ionomycin or PMA on ALCAM secretion and shedding, TPC-1 cells were treated with PV or EGF, or medium alone with or without CGS were then collected, centrifuged at 1000 rpm, and used undiluted for secreted ALCAM determination by measuring the cell-free area width at time 15 h later, by a Nikon DS-5M Camera System mounted on a phase-contrast Leitz microscope. The distance traveled by the cells was determined by measuring the cell-free area width at time 15 h and subtracting it from the cell-free area width at time 0. The values obtained were then expressed as % migration, setting the gap width at t₀ as 100%. Two experiments were done in triplicates.

**Immunohistochemistry (IHC)**

The IHC analyses were made using 2 µm of the formalin-fixed and paraffin-embedded tumoral sections with antibodies against ALCAM and CD36 as described in Mezzanzanica et al. [20] and in Scarpino et al., [10] respectively. All of the samples were also immunophenotyped using an anti-CD41 antibody (diluted 1:75), and the antigens were retrieved using 10 mM citrate buffer (pH 6.0) in an autoclave at 95°C for 15 min.

**Acknowledgments**

We thank Mrs. Cristina Mazzardi for secretarial help.

**Author Contributions**

Conceived and designed the experiments: FM IB. Performed the experiments: FM LDR PM SP. Analyzed the data: MF SF SC MAP.

**References**

1. Delellis RA, Williams ED (2004) Thyroid and parathyroid tumors. In: Delellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and genetics of tumors of endocrine organs. World health organization classification of tumours. Lyon: IARC Press. pp 51–6.
2. Wells SA, Jr., Franz C (2000) Medullary carcinoma of the thyroid gland. World J Surg 24: 952–6.
3. Jain S, Watson MA, De-Benedetti MK, Hiraki Y, Moley JF, et al. (2004) Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome cancers. Cancer Res 64: 3907–13.
4. Risco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, et al. (2009) The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69: 8317–25.
5. Savagner P (2003) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912–23.
6. García-Rostán G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, et al. (2004) CD166: A novel marker for aggressive tumor phenotypes and poor prognosis. Am J Pathol 150: 987–96.
7. Jarzab B, Wiencz M, Fujarewicz K, Smek K, Jarzab M, et al. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1387–97.
8. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, et al. (2007) Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 26: 7894–903.
9. Borrero MG, Alberti I, Fischer A, DegiInnocenti D, Ferrari C, et al. (2005) Induction of a proinflammatory programme in normal human thyrocytes by the RET/PTC1 oncogene. Proc Nad Acad Sci U S A 102: 14825–30.
10. Scarpino S, Di Na, Molto F, Talarico C, Cancrini A, et al. (2007) Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 212: 411–9.
11. El DD, Naar A, Alwani S (2008) Application of CD36, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3: 5.
12. Peinado H, Omeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415–26.
25. Davies SR, Dent C, Watkins G, King JA, Mokbel K, et al. (2008) Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep 19: 555–61.

26. Jezierska A, Matysiak W, Motyl T (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 12: 263–273.

27. Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, et al. (2010) MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene.

28. Rosso O, Piazza T, Bongarzone I, Rosello A, Mozzi A, et al. (2007) The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246–53.

29. Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, et al. (2008) Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 3: 2425.

30. Savina A, Furlan M, Vital M, Colombo MI (2003) Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 278: 29883–90.

31. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, et al. (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 103: 1783–97.

32. Garton KJ, Gough PJ, Raines EW (2006) Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 79: 1105–16.

33. Corrias MV, Gambani C, Gregorio A, Croce M, Barisone G, et al. (2010) Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse. Cell Oncol 32: 77–86.

34. Hart GW, Hosley MP, Slawson C (2007) Cycling of O-linked beta-N-acetylglicosamine on nucleocytoplasmic proteins. Nature 446: 1017–22.

35. Fenton CL, Patel A, Burch HB, Tuttle RM, Francis GL (2001) Nuclear localization of thyroid transcription factor-1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course. Ann Clin Lab Sci 31: 245–52.

36. Gorla L, Mondellini P, Cuccuru G, Micciche’ F, Casinelli G, et al. (2009) Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signalling elements. Molecular Carcinogenesis 48: 230–31.

37. Rodriguez-Antonio C, Pallares J, Montero-Conde C, Inglada-Perez L, Castellblanco E, et al. (2010) Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17: 7–16.

38. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La MO, et al. (2010) Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res 30: 473–80.

39. Basa V, De RS, Feliciello A, Altomonte M, Alleavato G, et al. (1998) Intercellular adhesion molecule-1 is upregulated via the protein kinase C pathway in human thyroid carcinoma cell lines. Thyroid 8: 23–28.

40. Caccia D, Micciche’ F, Casinelli G, Mondellini P, Casalini P, et al. (2010) Dasatinib reduces FAK phosphorylation increasing the effects of RPT1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer 9: 278.

41. Zimmerman AW, Nelissen JM, van Ernst-de Vries SE, Willems PH, de LF, et al. (2004) Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKCalpha independently of Rho-like GTPases. J Cell Sci 117: 2041–52.

42. Piazza T, Cia E, Bongarzone I, Canavari S, Bolognesi A, et al. (2005) Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci 118: 1515–25.